*This webinar has been rescheduled for Thursday, March 6
What is preventing increased orphan drug approvals, given the skyrocketing number of orphan drug designations granted by FDA? Join Avalere and industry experts to explore the space between orphan drug designation and approval, to discuss the challenges behind orphan drug approval and patient access, and to explain the implications of these issues on reimbursement in the new exchange landscape.
During this webinar, you will:
- Learn about the challenges preventing orphan drug approvals from matching the increasing number of orphan drug designations.
Understand how various stakeholders view the orphan drug business model, including global development of orphan drugs.
Learn about sponsor, patient and payer expectations for orphan drugs.
Brenda Huneycutt – Senior Manager, Avalere (moderator)
Sandy Robinson – Vice President, Avalere
Larry Bauer – Regulatory Scientist, Office of New Drugs, Rare Diseases Program, CDER, FDA
J. Russell Teagarden – Senior Vice President, Medical & Scientific Affairs, National Organization for Rare Disorders
Brendan Lanpher – Biochemical and Clinical Geneticist, The Center for Neuroscience and Behavioral Medicine, Children’s National Medical Center